^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    PNV21 vaccine

    i
    Other names: PNV21 vaccine, Neoantigen Peptide Vaccine
    Associations

    News

    Trials
    Company:
    Fred Hutchinson Cancer Center
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    5ms
    Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma or Hormone Receptor Positive Her2 Negative Metastatic Refractory Breast Cancer (clinicaltrials.gov)
    P1, N=20, Recruiting, Fred Hutchinson Cancer Center | Trial completion date: Nov 2025 --> Nov 2026 | Trial primary completion date: Nov 2024 --> Nov 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    Opdivo (nivolumab) • Hiltonol (poly-ICLC) • PNV21 vaccine
    11ms
    Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma or Hormone Receptor Positive Her2 Negative Metastatic Refractory Breast Cancer (clinicaltrials.gov)
    P1, N=20, Recruiting, Fred Hutchinson Cancer Center | Trial completion date: Nov 2024 --> Nov 2025
    Trial completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HR positive • BRAF mutation • HER-2 negative • PTEN mutation + HR positive
    |
    Opdivo (nivolumab) • Hiltonol (poly-ICLC) • PNV21 vaccine